Skip to main content
SpringerLink
Log in

Oral Beclomethasone Dipropionate as an Alternative to Systemic Steroids in Mild to Moderate Ulcerative Colitis Not Responding to Aminosalicylates

  • Original Article
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Backgroud

Aminosalicylates (5-ASA) are first-line treatment for mild-moderate ulcerative colitis (UC). Systemic corticosteroids (CS) are considered for patients in whom 5-ASA has been unsuccessful, but their use is limited by adverse effects. Beclomethasone dipropionate (BDP), a topically acting steroid with low systemic bioavailability, has a more favorable safety profile, but its role in clinical practice is not yet well established.

Aim

The aim of the present study is to assess whether oral BDP can be an alternative treatment to systemic CS for patients with mild-moderate UC not responding to first-line therapy with 5-ASA.

Methods

From 2003 to 2006, all consecutive patients with mild-moderate UC unresponsive to oral and topical 5-ASA (±topical CS) administered for at least 3 weeks received an 8-week course of oral BDP (10 mg/day for 4 weeks and 5 mg/day for an additional 4 weeks). Co-primary end-points were: (1) clinical remission within 8 weeks, without need of systemic CS; (2) steroid-free remission for 12 months.

Results

Sixty-four patients were included. In this study, within 8 weeks, 48/64 patients (75%) entered remission without systemic CS, while 16/64 (25%) failed to enter remission. Within 12 months, 37/64 patients (58%) had prolonged steroid-free remission, while 11/64 (17%) relapsed. During 1 year, 75% of patients receiving oral BDP could avoid systemic CS.

Conclusions

Oral BDP can avoid the use of systemic CS in the vast majority of patients with mild-moderate UC not responding to 5-ASA and could be considered as a second-line treatment for these patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Carter MJ, Lobo AJ, Travis SPL, On behalf of the IBD Section of the British Society of Gastroenterology. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2004;53(Suppl V):v1–v16.

    Article  PubMed  Google Scholar 

  2. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults (update). Am J Gastroenterol. 2004;99(7):1371–1385.

    Article  PubMed  Google Scholar 

  3. Travis SPL, Stange EF, Lémann M, For the European Crohn’s and Colitis Organisation (ECCO), et al. European evidence-based consensus on the management of ulcerative colitis: current management. J Crohn’s Colitis. 2008;2(1):24–62.

    Article  Google Scholar 

  4. Sutherland L, MacDonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2006;19(2):CD000543.

    Google Scholar 

  5. Marshall JK, Irvine EJ. Rectal aminosalicylates therapy for distal ulcerative colitis: a meta-analysis. Aliment Pharmacol Ther. 1995;9(3):293–300.

    PubMed  CAS  Google Scholar 

  6. Marshall JK, Irvine EJ. Putting rectal 5-aminosalicylic acid in its place: the role in distal ulcerative colitis. Am J Gastroenterol. 2000;95(7):1628–1636.

    Article  PubMed  CAS  Google Scholar 

  7. Cohen RD, Woseth DM, Thisted RA, et al. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol. 2000;95(5):1263–1276.

    Article  PubMed  CAS  Google Scholar 

  8. Safdi M, DeMicco M, Sninsky C, et al. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol. 1997;92(10):1867–1871.

    PubMed  CAS  Google Scholar 

  9. Marteau P, Probert CS, Lindgren S, et al. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut. 2005;54(7):960–965.

    Article  PubMed  CAS  Google Scholar 

  10. Vecchi M, Meucci G, Gionchetti P, et al. Oral versus combination mesalazine therapy in active ulcerative colitis: a double-blind, double-dummy, randomized multicentre study. Aliment Pharmacol Ther. 2001;15(2):251–256.

    Article  PubMed  CAS  Google Scholar 

  11. Regueiro M, Loftus EV Jr, Steinhart AH, et al. Medical management of left-sided ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trials. Inflamm Bowel Dis. 2006;12(10):979–994.

    Article  PubMed  Google Scholar 

  12. Travis SPL. Review article: induction therapy for patients with active ulcerative colitis. Aliment Pharmacol Ther. 2006;15(1):10–16.

    Article  Google Scholar 

  13. Faubion WA, Loftus EV, Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. 2001;121:255–260.

    Article  PubMed  CAS  Google Scholar 

  14. Ho GT, Chiam P, Drummond H, et al. The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5-year UK inception cohort. Aliment Pharmacol Ther. 2006;24:319–330.

    Article  PubMed  CAS  Google Scholar 

  15. Plevy SE. Corticosteroid-sparing treatments in patients with Crohn’s disease. Am J Gastroenterol. 2002;97:1607–1617.

    Article  PubMed  Google Scholar 

  16. Harris DM. Some properties of beclomethasone dipropionate and related steroids in man. Postgrad Med J. 1975;51:20–25.

    PubMed  CAS  Google Scholar 

  17. Manguso F, Balzano A. Meta-analysis: the efficacy of rectal beclomethasone dipropionate vs. 5-aminosalicylic acid in mild to moderate distal ulcerative colitis. Aliment Pharmacol Ther. 2007;26(1):21–29.

    Article  PubMed  CAS  Google Scholar 

  18. Biancone L, Gionchetti P, del Vecchio Blanco G, et al. Beclomethasone dipropionate versus mesalazine in distal ulcerative colitis: a multicenter, randomized, double-blind study. Dig Liver Dis. 2007;39(4):329–337.

    Article  PubMed  CAS  Google Scholar 

  19. Gionchetti P, D’Arienzo A, Rizzello F, Italian BDP Study Group, et al. Topical treatment of distal active ulcerative colitis with beclomethasone dipropionate or mesalamine: a single-blind randomized controlled trial. J Clin Gastroenterol. 2005;39(4):291–297.

    Article  PubMed  CAS  Google Scholar 

  20. D’Arienzo A, Manguso F, Castiglione GN, et al. Beclomethasone dipropionate (3 mg) enemas combined with oral 5-ASA (2.4 g) in the treatment of ulcerative colitis not responsive to oral 5-ASA alone. Ital J Gastroenterol Hepatol. 1998;30(3):254–257.

    PubMed  Google Scholar 

  21. Campieri M, Cottone M, Miglio F, et al. Beclomethasone dipropionate enemas versus prednisolone sodium phosphate enemas in the treatment of distal ulcerative colitis. Aliment Pharmacol Ther. 1998;12(4):361–366.

    Article  PubMed  CAS  Google Scholar 

  22. Steed KP, Hooper G, Ventura P, et al. The in vivo behaviour of a colonic delivery system. Pharmaceutical Profiles Limited study no. PPL-015. Nottingham, 3rd April 1992. Int J Pharm. 1994;112:199–206.

    Article  CAS  Google Scholar 

  23. Campieri M, Adamo S, Valpiani D, et al. Oral beclomethasone dipropionate in the treatment of extensive and left-sided active ulcerative colitis: a multicenter randomised study. Aliment Pharmacol Ther. 2003;17(12):1471–1480.

    Article  PubMed  CAS  Google Scholar 

  24. Rizzello F, Gionchetti P, D’Arienzo A, et al. Oral beclomethasone dipropionate in the treatment of active ulcerative colitis: a double-blind placebo-controlled study. Aliment Pharmacol Ther. 2002;16(6):1109–1116.

    Article  PubMed  CAS  Google Scholar 

  25. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ. 1989;298(6666):82–86.

    Article  PubMed  CAS  Google Scholar 

  26. Travis S. Review article: the management of mild to severe acute ulcerative colitis. Aliment Pharmacol Ther. 2004;20(Suppl. 4):88–92.

    Article  PubMed  Google Scholar 

  27. Hanauer SB, Sandborn WJ, Kornbluth A, et al. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol. 2005;100(11):2478–2485.

    Article  PubMed  CAS  Google Scholar 

  28. Hanauer SB, Sandborn WJ, Dallaire C, et al. Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: the ASCEND I trial. Can J Gastroenterol. 2007;21(12):827–834.

    PubMed  CAS  Google Scholar 

  29. Hanauer SB. Review article: high-dose aminosalicylates to induce and maintain remissions in ulcerative colitis. Aliment Pharmacol Ther. 2006;24(Suppl 3):37–40.

    Article  PubMed  CAS  Google Scholar 

  30. Kruis W, Bar-Meir S, Feher J, et al. The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine. Clin Gastroenterol Hepatol. 2003;1(1):36–43.

    Article  PubMed  CAS  Google Scholar 

  31. Safdi AV, Cohen RD. Review article: increasing the dose of oral mesalazine therapy for active ulcerative colitis does not improve remission rates. Aliment Pharmacol Ther. 2007;26(9):1179–1186.

    PubMed  CAS  Google Scholar 

  32. Bergman R, Parkes M. Systematic review: the use of mesalazine in inflammatory bowel disease. Aliment Pharmacol Ther. 2006;23(7):841–855.

    Article  PubMed  CAS  Google Scholar 

  33. Rizzello F, Gionchetti P, Galeazzi R, et al. Oral beclomethasone dipropionate in patients with mild to moderate ulcerative colitis: a dose-finding study. Adv Ther. 2001;18(6):261–271.

    Article  PubMed  CAS  Google Scholar 

  34. Manes G, Imbesi V, Ardizzone S, et al. Appropriateness and diagnostic yield of colonoscopy in the management of patients with ulcerative colitis: a prospective study in an open access endoscopy service. Inflamm Bowel Dis. 2008;14(8):1133–1138.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Gastroenterology Unit, S. Filippo Neri Hospital, Rome, Italy

    Claudio Papi, Annalisa Aratari, Alessandra Moretti, Manuela Mangone, Giovanna Margagnoni, Maurizio Koch & Lucio Capurso

  2. UOC Gastroenterologia, Ospedale S. Filippo Neri, Via Martinotti 20, 00135, Rome, Italy

    Claudio Papi

Authors
  1. Claudio Papi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Annalisa Aratari
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alessandra Moretti
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Manuela Mangone
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Giovanna Margagnoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Maurizio Koch
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Lucio Capurso
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Claudio Papi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Papi, C., Aratari, A., Moretti, A. et al. Oral Beclomethasone Dipropionate as an Alternative to Systemic Steroids in Mild to Moderate Ulcerative Colitis Not Responding to Aminosalicylates. Dig Dis Sci 55, 2002–2007 (2010). https://doi.org/10.1007/s10620-009-0962-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-009-0962-6

Keywords

Search

Navigation